dihydroergotamine mesylate · Satsuma Pharms · NDA 217901
Atzumi
Earliest generic entry, as listed
12 Oct 2041
Blocked by patent: US 11744967, US 12102754.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11744967 | drug product · sets the listed date | 12 Oct 2041 |
| US 12102754 | drug product · sets the listed date | 12 Oct 2041 |
| US 10758532 | drug product | 11 Dec 2039 |
| US 12263162 | drug product | 11 Dec 2039 |
| US 10792253 | drug product | 4 Aug 2037 |
| US 11872314 | drug product | 4 Aug 2037 |
| US 12594273 | drug product | 24 Sep 2033 |
Exclusivities · 1 unexpired
| NP | new product | 30 Apr 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217901 · 001 · RLD | powder, nasal | EQ 5.2MG BASE | 12 Oct 2041 |